Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN
he Menarini Group continues to stand firmly by the side of the Tommasino Bacciotti Foundation
Elcin Barker Ergun, CEO of the Menarini Group, comments in a recent interview with ANSA what Menarini continues to do in the fight against the pandemic
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.
Menarini Ricerche today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611,
Page 1 of 6First   Previous   [1]  2  3  4  5  6  Next   Last